LYRA Lyra Therapeutics Inc

Price (delayed)

$0.305

Market cap

$18.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.2

Enterprise value

$38.66M

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose ...

Highlights
Lyra Therapeutics's gross profit has increased by 29% YoY and by 8% from the previous quarter
The company's revenue rose by 29% YoY and by 8% QoQ
LYRA's equity is up by 17% year-on-year but it is down by 13% since the previous quarter
The debt has grown by 41% since the previous quarter
LYRA's quick ratio is down by 20% YoY and by 10% from the previous quarter

Key stats

What are the main financial stats of LYRA
Market
Shares outstanding
60.96M
Market cap
$18.59M
Enterprise value
$38.66M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.24
Price to sales (P/S)
11.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.01
Earnings
Revenue
$1.68M
EBIT
-$68.82M
EBITDA
-$68.69M
Free cash flow
-$73.06M
Per share
EPS
-$1.2
Free cash flow per share
-$1.14
Book value per share
$1.3
Revenue per share
$0.03
TBVPS
$2.21
Balance sheet
Total assets
$141.53M
Total liabilities
$64.02M
Debt
$37.86M
Equity
$77.5M
Working capital
$70.72M
Liquidity
Debt to equity
0.49
Current ratio
4.78
Quick ratio
4.76
Net debt/EBITDA
-0.29
Margins
EBITDA margin
-4,088.6%
Gross margin
100%
Net margin
-4,099.8%
Operating margin
-4,364.9%
Efficiency
Return on assets
-51.9%
Return on equity
-78.8%
Return on invested capital
-67.5%
Return on capital employed
-56%
Return on sales
-4,096.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LYRA stock price

How has the Lyra Therapeutics stock price performed over time
Intraday
5.17%
1 week
12.96%
1 month
1.67%
1 year
-90.03%
YTD
-94.18%
QTD
8.93%

Financial performance

How have Lyra Therapeutics's revenue and profit performed over time
Revenue
$1.68M
Gross profit
$1.68M
Operating income
-$73.33M
Net income
-$68.88M
Gross margin
100%
Net margin
-4,099.8%
Lyra Therapeutics's gross profit has increased by 29% YoY and by 8% from the previous quarter
The company's revenue rose by 29% YoY and by 8% QoQ
The company's operating income fell by 19% YoY and by 9% QoQ
Lyra Therapeutics's net income has decreased by 16% YoY and by 10% QoQ

Growth

What is Lyra Therapeutics's growth rate over time

Valuation

What is Lyra Therapeutics stock price valuation
P/E
N/A
P/B
0.24
P/S
11.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.01
The EPS is up by 26% year-on-year and by 4.8% since the previous quarter
LYRA's price to book (P/B) is 92% less than its last 4 quarters average of 2.9 and 90% less than its 5-year quarterly average of 2.1
LYRA's equity is up by 17% year-on-year but it is down by 13% since the previous quarter
The price to sales (P/S) is 94% lower than the last 4 quarters average of 176.5
The company's revenue rose by 29% YoY and by 8% QoQ

Efficiency

How efficient is Lyra Therapeutics business performance
LYRA's return on invested capital has surged by 67% year-on-year and by 13% since the previous quarter
The return on equity has declined by 14% year-on-year and by 6% since the previous quarter
The ROS is up by 10% year-on-year

Dividends

What is LYRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LYRA.

Financial health

How did Lyra Therapeutics financials performed over time
The total assets is 121% greater than the total liabilities
Lyra Therapeutics's total liabilities has surged by 130% YoY and by 20% QoQ
The total assets has surged by 51% year-on-year
The debt is 51% smaller than the equity
The company's debt to equity has surged by 63% QoQ
The debt has grown by 41% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.